How do you choose between atezolizumab, bevacizumab, carboplatin, paclitaxel (IMpower 150) vs. pembrolizumab plus chemotherapy (KEYNOTE 189) in patients with metastatic NSCLC?
Answer from: Medical Oncologist at Community Practice
This is a great question. As we are all well aware, the combination of chemotherapy and immunotherapy has become a standard of care for some patients with advanced non-squamous NSCLC. Both the IMPOWER trial published by Socinski et al. in NEJM and the KEYNOTE 189 trial published by Gandhi et al. in ...
Comments
Medical Oncologist at Gerard J Ventura MD, FACP For patients with documented EGFR mutation who hav...
Medical Oncologist at Blue Ridge Cancer Care I think generic pemetrexed will answer this questi...
Medical Oncologist at St. Bernards Medical Center Personally, try to use the Avastin combination in ...
For patients with documented EGFR mutation who hav...
I think generic pemetrexed will answer this questi...
Personally, try to use the Avastin combination in ...